Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression

Biological Psychiatry

Volumn 67, Issue 2, 2010, Pages 139-145

  aan het Rot, Marije ^a   Collins, Katherine A ^a   Murrough, James W ^a   Perez, Andrew M ^a   Reich, David L ^a   Charney, Dennis S ^a   Mathew, Sanjay J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamate; investigational therapies; ketamine; major depressive disorder; NMDA receptors; treatment resistance

Indexed keywords

KETAMINE;

ADULT; AGED; ARTICLE; BLURRED VISION; BRADYCARDIA; BRADYPNEA; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; HYPOTENSION; MALE; MEMORY DISORDER; MENTAL CAPACITY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OPEN STUDY; OUTPATIENT CARE; OXYGEN SATURATION; PARESTHESIA; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TACHYCARDIA; UNSTEADINESS; VITAL SIGN; WEAKNESS;

ADULT; AGED; ANALGESICS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISK ASSESSMENT; TIME FACTORS;

EID: 71649098114     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2009.08.038     Document Type: Article

References (24)

1. Green S.M., and Li J. Ketamine in adults: What emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med 7 (2000) 278-281
2. Krystal J.H., D'Souza D.C., Karper L.P., Bennett A., Abi-Dargham A., Abi-Saab D., et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 145 (1999) 193-204
3. Krystal J.H., Madonick S., Perry E., Gueorguieva R., Brush L., Wray Y., et al. Potentiation of low dose ketamine effects by naltrexone: Potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology 31 (2006) 1793-1800
4. Javitt D.C. Glutamate and schizophrenia: Phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78 (2007) 69-108
5. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., and Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000) 351-354
6. Zarate Jr. C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006) 856-864
7. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) (2001), New York State Psychiatric Institute, Biometrics Research, New York
8. Sackeim H.A. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62 suppl 16 (2001) 10-17
9. Mathew S.J., Murrough J.W., aan het Rot M., Collins K.A., Reich D.L., and Charney D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial. [published online ahead of print March 17]. Int J Neuropsychopharmacol (2009) doi:10.1017/S1461145709000169
10. Rush A.J., Carmody T.J., Ibrahim H.M., Trivedi M.H., Biggs M.M., Shores-Wilson K., et al. Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatr Serv 57 (2006) 829-837
11. Price R.B., Nock M.K., Charney D.S., and Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66 (2009) 522-526
12. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep 10 (1962) 799-812
13. Bremner J.D., Krystal J.H., Putnam F.W., Southwick S.M., Marmar C., Charney D.S., et al. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11 (1998) 125-136
14. Levine J., and Schooler N.R. SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22 (1986) 343-381
15. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979) 382-389
16. Lenderking W.R., Hu M., Tennen H., Cappelleri J.C., Petrie C.D., and Rush A.J. Daily process methodology for measuring earlier antidepressant response. Contemp Clin Trials 29 (2008) 867-877
17. Duncan E.J., Madonick S.H., Parwani A., Angrist B., Rajan R., Chakravorty S., et al. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25 (2001) 72-83
18. Lahti A.C., Warfel D., Michaelidis T., Weiler M.A., Frey K., and Tamminga C.A. Long-term outcome of patients who receive ketamine during research. Biol Psychiatry 49 (2001) 869-875
19. Goldberg M.E., Domsky R., Scaringe D., Hirsh R., Dotson J., Sharaf I., et al. Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome. Pain Physician 8 (2005) 175-179
20. Mills I.H., Park G.R., Manara A.R., and Merriman R.J. Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. Q J Med 91 (1998) 493-503
21. Tsai G.E. Searching for rational anti N-methyl-D-aspartate treatment for depression. Arch Gen Psychiatry 64 (2007) 1099-1100
22. Correll G.E., and Futter G.E. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 7 (2006) 92-95
23. Sackeim H.A., Haskett R.F., Mulsant B.H., Thase M.E., Mann J.J., Pettinati H.M., et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: A randomized controlled trial. JAMA 285 (2001) 1299-1307
24. Kellner C.H., Knapp R.G., Petrides G., Rummans T.A., Husain M.M., Rasmussen K., et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: A multisite study from the Consortium for Research in electroconvulsive therapy (CORE). Arch Gen Psychiatry 63 (2006) 1337-1344